<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6011">
  <stage>Registered</stage>
  <submitdate>27/05/2016</submitdate>
  <approvaldate>27/05/2016</approvaldate>
  <nctid>NCT02788474</nctid>
  <trial_identification>
    <studytitle>Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment</studytitle>
    <scientifictitle>A 12-week, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Followed by a Single Active Arm Phase of 40 Weeks Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on Change in Biomarkers of Extracellular Matrix (ECM) Turnover in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Limited Forced Vital Capacity (FVC) Impairment.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-003148-38</secondaryid>
    <secondaryid>1199.227</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Idiopathic Pulmonary Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - nintedanib
Treatment: drugs - placebo

Placebo Comparator: placebo - 

Experimental: nintedanib - 


Treatment: drugs: nintedanib


Treatment: drugs: placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The rate of change (slope) in blood C-reactive protein degraded by metalloproteinase-1/8 (CRPM) from baseline to week 12.</outcome>
      <timepoint>baseline and 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of patients with disease progression as defined by absolute forced vital capacity decline &gt;=10% or death until week 52</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The rate of change in blood Collagen 3 degraded by metalloproteinase-9 (C3M) from baseline to week 12</outcome>
      <timepoint>baseline and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The rate of change in blood Collagen 1 degraded by metalloproteinase-2/9/13 (C1M) from baseline to week 12</outcome>
      <timepoint>baseline and 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Written informed consent consistent with International Conference on Harmonisation
             Good Clinical Practice and local laws, signed prior to participation in the trial
             including any study related procedures being performed;

          -  Male or female patients aged &gt;=40 years at Visit 1;

          -  A clinical diagnosis of Idiopathic pulmonary fibrosis (IPF) within the last 3 years
             from visit 0, based upon the American Thoracic Society/ European Respiratory Society
             /Japanese Respiratory Society/ Latin American Thoracic Association 2011 guideline;

          -  Chest high resolution computed tomography (HRCT) scan performed within 18 months of
             Visit 0;

          -  Combination of HRCT pattern, and surgical lung biopsy pattern (the latter if
             available) as assessed by central review are consistent with the diagnosis of
             Idiopathic pulmonary fibrosis;

          -  Forced vital capacity (FVC) &gt;=80% of predicted normal at Visit 1.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Alanine transaminase, Aspartate aminotransferase &gt; 1.5 fold upper limit of normal
             (ULN) at Visit 1;

          -  Total bilirubin &gt; 1.5 fold ULN at Visit 1;

          -  Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic
             impairment);

          -  Relevant airways obstruction, i.e. pre-bronchodilator Forced expiratory volume in 1
             second / Forced vital capacity &lt; 0.70;

          -  History of myocardial infarction within 6 months of visit 1 or unstable angina within
             1 month of Visit 1;

          -  Bleeding Risk:

               -  Known genetic predisposition to bleeding;

               -  Patients who require fibrinolysis, full-dose therapeutic anticoagulation or high
                  dose antiplatelet therapy;

               -  History of haemorrhagic central nervous system (CNS) event within 12 months prior
                  to Visit 1;

               -  History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers
                  and/or major injury or surgery within 3 months prior to Visit 1;

               -  International normalised ratio (INR) &gt; 2 at Visit 1;

               -  Prothrombin time (PT) and partial thromboplastin time (PTT) &gt; 150% of ULN at
                  Visit 1;

          -  Planned major surgery during the trial participation, including lung transplantation,
             major abdominal or major intestinal surgery;

          -  History of thrombotic event (including stroke and transient ischemic attack) within 12
             months of Visit 1;

          -  Creatinine clearance &lt; 30 mL/min calculated by Cockcroft-Gault formula at Visit 1;

          -  Treatment with nintedanib, pirfenidone, azathioprine, cyclophosphamide, cyclosporine,
             any other investigational drug, n-acetylcysteine, prednisone/prednisolone &gt;15 mg daily
             or &gt;30 mg every 2 days OR use of other systemic corticosteroids as well as any
             investigational drugs within 4 weeks of Visit 2;

          -  Known hypersensitivity to nintedanib, peanut, soya or to any other components of the
             study medication;

          -  Prior discontinuation of nintedanib treatment due to intolerability/ adverse events
             considered drug related;

          -  A disease or condition which in the opinion of the investigator may interfere with
             testing procedures or put the patient at risk when participating in this trial;

          -  Alcohol or drug abuse which in the opinion of the treating physician would interfere
             with the treatment and would affect patient's ability to participate in this trial;

          -  Patients not able to understand and follow any study procedures such as but not
             limited to home spirometry, including completion of self-administered questionnaires
             without help;

          -  Women who are pregnant, nursing, who plan to become pregnant while in the trial or
             female patients with positive pregnancy (ß-HCG) test at Visit 1 and/or Visit 2;

          -  Women of childbearing potential4 not willing or able to use highly effective methods
             of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per
             year when used consistently and correctly.

          -  Patients with acute IPF exacerbation or any respiratory tract infection in the four
             weeks prior to Visit 1 or during the screening period;

          -  Patients who are or have been participating in another trial with investigational
             drug/s within one month prior to Visit 1 and patients who have previously been
             enrolled in this trial;

          -  Further exclusion criteria apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>9/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>347</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>11/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown, Sydney</hospital>
    <hospital>Concord General Repatriation Hospital -Ambulatory Care Unit - Concord</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>The Alfred Hospital- Respiratory Medicine - Melbourne</hospital>
    <postcode>2050 - Camperdown, Sydney</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liège</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Yvoir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Usti nad Labem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Oulu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bamberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Greifswald</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Grosshansdorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Immenhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Münster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Deszk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Farkasgyepu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi, Seto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka, Kurume</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ibaraki, Naka-gun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa, Yokohama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka, Osakasayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokushima, Tokushima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo, Bunkyo-ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo, Ota-ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo, Shinjuku-ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seongnam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Torun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Galdakao</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>L'Hospitalet Llobregat (BCN)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Majadahonda (Madrid)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pozuelo de Alarcón</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sabadell</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Exeter</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Identifying biomarkers to predict the clinical course and benefits of therapy early in the
      course of the disease remains one of the most urgent and relevant challenges to improve
      overall patient management, to prevent treatment delay or overtreatment. This study is
      conducted to examine the effect of nintedanib treatment on change in biomarkers indicative of
      extracellular matrix turnover which have been shown recently to correlate with disease
      progression. This study further aims to confirm the association of biomarker course during
      the first three months of treatment and disease progression.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02788474</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>